Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION-13 inclisiran in adolescents with homozygous familial hypercholesterolemia
NL-OMON54036Phase 3Recruiting
- Sponsor
- Novartis
- Start
- May 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in homozygous familial hypercholesterolemia (HoFH) comparing Inclisiran → open-label inclisiran with Placebo → open-label inclisiran (2 arms). Primary endpoint: Percent change in LDL-cholesterol at Day 330. Started May 2021; status: recruiting.
02
Drugs
inclisiran
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NL-OMON54036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54036.